Human — Older adults enrolled in the SmartAge RCT   Tier 2 · Human clinical/functional RCT verification: verified
1. Species / populationOlder adult humans, SmartAge RCT, n=100
2. Exposure, route, schedule0.9 mg/day spermidine equivalent via wheat germ extract, oral, daily
3. Comparator & durationPlacebo, 12 months
4. Endpoint & numeric resultPrimary cognitive composite: difference -0.03 (95% CI -0.11 to 0.05), p=.47 -- no effect
5. What this study did NOT establishNo lifespan data; no significant cognitive effect at tested dose/duration; no cross-unit conversion to animal drinking-water doses
Intervention(s)Spermidine
SpeciesHuman
PopulationOlder adults enrolled in the SmartAge RCT
Sample size100 participants verification: verified_2026-07-11
Exposure0.9 mg/day spermidine (via wheat germ extract) — Daily oral dosing verification: verified_2026-07-11
ComparatorPlacebo
Duration12 months
EndpointPrimary: cognitive composite score change
Evidence tierTier 2 · Human clinical/functional RCT
What was NOT establishedDid not test lifespan. No significant cognitive benefit found at this dose/duration/formulation. Does not establish effects of higher doses, pure-compound dosing, or the mM-in-drinking-water exposures used in the mouse/rat studies on the spermidine intervention page -- unit conversion between mg wheat-germ-extract and mM drinking water is NOT established.
primary endpoint difference-0.03
confidence interval 95-0.11 to 0.05
p valuep = .47
interpretationNo significant effect
verificationverification: verified_2026-07-11
Verification status: verified This record was checked against its primary publication on 2026-07-11.Identifiers: PMID verified; DOI verified; PMC verified; trial registry ID not reported. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that does not apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
trial nameSmartAge
pmid35616942 verified
doi10.1001/jamanetworkopen.2022.13875 verified
journalJAMA Network Open 2022
trial registry idnot reported not reported
pmcPMC9136623 verified
authorsSchwarz C, Benson GS, Horn N, et al. (SmartAge)
year2022
verified date2026-07-11
verified noten=100, 60-90 yo SCD, 0.9 mg/d wheat-germ spermidine vs placebo, 12 mo; primary mnemonic-discrimination NOT significantly improved — MATCHES (null result confirmed).
verification statusverified

Funding / conflict of interest

not compiled in this proof-of-concept verification: verified_2026-07-11

Version 0.1.0-poc · literature search date 2026-07-11 · editorial owner Nabus Research